Imagen de Portada

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial

Background Primary analyses of a study in young women aged 16–26 years showed efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccine against infections and disease related to HPV 31, 33, 45, 52, and 58, and non-inferior HPV 6, 11, 16, and 18 antib...

Descripción completa

Detalles Bibliográficos
Autores Principales: Huh, Warner, Joura, Elmar A., Giuliano, Anna R, Iversen, Ole-Erik, de Andrade, Rosires Pereira, Ault, Kevin A, Bartholomew, Deborah, Cestero, Ramon M, Fedrizzi, Edison N, Hirschberg, Angelica L, Mayrand, Marie-Hélène, Stapleton, Jack T, Wiley, Dorothy J, Ferenczy, Alex, Kurman, Robert, Ronnett, Brigitte M, Stoler, Mark H, Cuzick, Jack, Garland, Suzanne M., Kjaer, Susanne K, Bautista, Oliver M, Haupt, Richard, Moeller, Erin, Ritter, Michael, Roberts, Christine C, Shields, Christine, Luxembourg, Alain, Ruiz-Sternberg, Angela María
Formato: Artículo (Article)
Lenguaje:Inglés (English)
Publicado: Lancet Publishing Group 2017
Materias:
Virus DNA
Wart virus vaccine
Virus antibody
Adenocarcinoma in situ
Adolescent
Adult
Anaphylaxis
Antibody blood level
Antibody response
Antibody titer
Appendicitis
Article
Cancer incidence
Cancer prevention
Controlled study
Double blind procedure
Drug efficacy
Drug safety
Female
Fetus wastage
Follow up
Human
Human experiment
Human papillomavirus type 11
Human papillomavirus type 16
Human papillomavirus type 18
Human papillomavirus type 31
Human papillomavirus type 33
Human papillomavirus type 45
Human papillomavirus type 52
Human papillomavirus type 58
Human papillomavirus type 6
Human tissue
Immunoassay
Incidence
Infection prevention
Intention to treat analysis
Multicenter study
Nonhuman
Normal human
Outcome assessment
Persistent virus infection
Priority journal
Randomized controlled trial
Seroconversion
Side effect
Spontaneous abortion
Uterine cervix carcinoma
Uterine cervix carcinoma in situ
Uterine cervix cytology
Vaccination
Vaccine immunogenicity
Vaginal intraepithelial neoplasia
Vulva cancer
Blood
Clinical trial
Dose response
Immunology
Intramuscular drug administration
Papillomavirus infection
Patient compliance
Patient safety
Primary prevention
Procedures
Statistics and numerical data
Treatment outcome
Uterine cervix tumor
Virology
Young adult
Double-Blind Method
Follow-Up Studies
Human papillomavirus 6
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
Humans
Papillomavirus Infections
Patient Compliance
Patient Safety
Primary Prevention
Treatment Outcome
Uterine Cervical Neoplasms
Young Adult
Intramuscular
Drug
Viral
Vaccine
Antibodies
Dose-Response Relationship
Immunogenicity
Injections
Acceso en línea:https://repository.urosario.edu.co/handle/10336/23374
https://doi.org/10.1016/S0140-6736(17)31821-4

Internet

https://repository.urosario.edu.co/handle/10336/23374
https://doi.org/10.1016/S0140-6736(17)31821-4

Ejemplares similares